Genenta Science (GNTA), a leader in cell-based immuno-oncology therapies, Wednesday announced that it has partnered with Italian biotech manufacturer Anemocyte to produce key starting materials for its clinical development, including cell banks and plasmids for viral vector production.
The alliance underscores the synergy between Genenta's platform and Anemocyte's manufacturing expertise.
Genenta's Chief Medical Officer, Dr. Carlo Russo, credited Anemocyte's team for playing a crucial role in the successful execution of the manufacturing process, confirming the partner's reliability and product quality. Anemocyte CEO Marco Ferrari praised Genenta's Nasdaq listing and highlighted the collaboration as a strong example of Italy's progress in cell and gene therapy, driven by innovation, quality, and sustainability.
GNTA is currently trading at $4.0787 or 1.71% higher on the Nasdaq Capital Market.
For comments and feedback: editorial@rttnews.com